Результаты поиска

Management of Itch in the Elderly: A Review.

Chronic itch is common in the elderly patient and may be caused by a variety of known dermatologic and non-dermatologic conditions and can have a significant effect on quality of life. Age-related changes in barrier function, immunosenescence, and neuronal changes and neuropathies are common predisposing factors to chronic itch in this age group. Certain primary dermatologic conditions are more common in the elderly and can cause chronic itch. Also, co-morbid diseases particularly of the renal, hepatobiliary, or hematologic systems, psychologic conditions, or medications may contribute to chro

Совпадение в полном тексте источника
… Dermatologic medications used for itch-related diseases that undergo renal clearance and thus require consideration of renal dosing include cetirizine and gabapentin, among others [ 88 ]. …

Proceedings of the Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2018

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the global, randomised, double-blind, placebo-controlled Phase III TOURMALINE-MM1 study of ixazomib-Rd (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma. IRd resulted in a significant improvement in progression-free survival versus placebo-Rd (median: 20·6 vs. 14·7 months; hazard

Совпадение в полном тексте источника
… Management approaches included antihistamines (primarily cetirizine) or topical glucocorticoids. …

The Roles of EDA2R in Ageing and Disease.

Ageing is a complex biological process driven, in part, by inflammaging. Recent research identifies the ectodysplasin A2 receptor (EDA2R) as a key regulator of inflammaging and a novel biomarker of ageing, with its expression increasing with age across diverse tissues in humans and animal models. Elevated EDA2R gene expression is associated with accelerated ageing, cellular senescence, frailty, obesity, acne, radiation response and increased levels of inflammatory, renal, cardiac and vascular biomarkers. Similarly, elevated EDA2R protein levels, a critical component of the proteomic ageing clo

Совпадение в полном тексте источника
… Therapies under investigation include cetirizine, stem cell exosomes, platelet‐rich plasma and gene‐targeted approaches to restore follicular function (Abdin et al. 2022 ; Papukashvili et al. 2021 ; Tang et al. 2023 ; Zaky et al. 2021 ). …

Alcohol Consumption and Autoimmune Diseases.

Alcohol is the second-most misused substance after tobacco. It has been identified as a causal factor in more than 200 diseases and 5.3% of all deaths and is associated with significant behavioral, social, and economic difficulties. As alcohol consumption may modulate the immune system's regulatory mechanisms to avoid attacking the body's tissues, it has been proven to play a dichotomic role in autoimmune diseases (ADs) based on the quantity of consumption. In this review, we report updated evidence on the role of alcohol in ADs, with a focus on alcohol addiction and the human biological immun

Совпадение в полном тексте источника
… Environmental control measures to reduce exposure to identified allergens are necessary, but patients may benefit from antihistamines (e.g., cetirizine, loratadine), intranasal corticosteroids (e.g., fluticasone, mometasone), decongestants, leukotriene receptor antagonists (e.g., montelukast), and sometimes …

The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors.

Background: The emergence of multidrug-resistant organisms (MDROs) is a global public health issue, severely hindering clinicians in administering appropriate antimicrobial therapy. Drug repurposing is a drug development strategy, during which new pharmacological applications are identified for already approved drugs. From the viewpoint of the development of virulence inhibitors, inhibition of quorum sensing (QS) is a promising route because various important features in bacterial physiology and virulence are mediated by QS-dependent gene expression. Methods: Forty-five pharmacological agents,

Совпадение в полном тексте источника
… fluconazole (SA), terbinafine (GlaxoSmithKline Hungary Ltd., Budapest, Hungary), 3. anthelmintic drugs: mebendazole (Richter Pharmaceuticals; Budapest, Hungary; will be listed as RPh in the subsequent text), ivermectin (SA), 4. anti-allergy medications (H 1 -receptor antagonists and decongestants): cetirizine …

Unveiling the Complexities of Hereditary Angioedema.

Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder, constituting approximately 2% of all clinical cases of angioedema, with a global prevalence estimated between 1 in 50,000 and 1 in 150,000 individuals. The condition affects individuals of all genders and ethnic backgrounds without significant variation. HAE is classified into three types. Type I HAE, which accounts for 85% of cases, is characterized by a deficiency of the C1 esterase inhibitor (C1-INH) gene. Type II HAE, making up 15% of cases, involves a dysfunctional C1-INH. Type III HAE, which represen

Совпадение в полном тексте источника
… normal or near-normal levels of C4, as well as antigenic and functional C1-INH; the presence of a genetic mutation defects in one of the six genes as follows: FXII, PLG, ANGPT1, KNG1, MYOF, and HS3ST6; a positive family history of angioedema, or a lack of efficacy of high-dose antihistamines (e.g., cetirizine …

Emerging biologic frontiers for Sjogren's syndrome: Unveiling novel approaches with emphasis on extra glandular pathology.

Primary Sjögren's Syndrome (pSS) is a complex autoimmune disorder characterized by exocrine gland dysfunction, leading to dry eyes and mouth. Despite growing interest in biologic therapies for pSS, FDA approval has proven challenging due to trial complications. This review addresses the absence of a molecular-target-based approach to biologic therapy development and highlights novel research on drug targets and clinical trials. A literature search identified potential pSS treatment targets and recent advances in molecular understanding. Overlooking extraglandular symptoms like fatigue and depr

Совпадение в полном тексте источника
… When these measures are insufficient, antihistamines such as cetirizine, fexofenadine, and famotidine should be considered. In instances resistant to conventional treatments, oral corticosteroids may be used. …

Respiratory and Thoracic Medicine

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… hours Enrofloxacin 2.5-5 mg/kg, PO, every 24 hours Marbofloxacin 2.5-5 mg/kg, PO, every 24 hours Metronidazole 10-15 mg/kg, PO, every 12 hours Orbifloxacin 2.5-5 mg/kg, PO, every 24 hours Pradofloxacin 5-10 mg/kg, PO, every 24 hours Trimethoprim-sulfonamide 15 mg/kg, PO, every 12 hours Antihistamines Cetirizine … Enrofloxacin | 2.5-5 mg/kg, PO, every 24 hours Marbofloxacin | 2.5-5 mg/kg, PO, every 24 hours Metronidazole | 10-15 mg/kg, PO, every 12 hours Orbifloxacin | 2.5-5 mg/kg, PO, every 24 hours Pradofloxacin | 5-10 mg/kg, PO, every 24 hours Trimethoprim-sulfonamide | 15 mg/kg, PO, every 12 hours Antihistamines | Cetirizine …

Chronic pruritus: a narrative review.

Chronic pruritus encompasses a manifestation of several cutaneous, allergic, infectious, neurological, psychological, and systemic conditions, whose etiological investigation and therapeutic strategy can be challenging. This comprehensive review aims to enhance the understanding of pruritus by highlighting important elements in its pathogenesis, including keratinocytes, Merkel cells and mast cells, nerve fibers, histaminergic and nonhistaminergic pathways, and the interaction of itch signals with the central nervous system. Diagnostic evaluation of chronic pruritus may require a meticulous app

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.

The paradigm of pediatric drug development has been evolving in a "carrot-and-stick"-based tactic to address population-specific issues. However, the off-label prescription of adult medicines to pediatric patients remains a feature of clinical practice, which may compromise the age-appropriate evaluation of treatments. Therefore, the United States and the European Pediatric Formulation Initiative have recommended applying nanotechnology-based delivery systems to tackle some of these challenges, particularly applying inorganic, polymeric, and lipid-based nanoparticles. Connected with these, adv

Совпадение в полном тексте источника
… However, some drugs, such as levetiracetam, cimetidine, and cetirizine, have demonstrated a similar or greater renal excretion rate in infants and preschool children than in adults [ 69 ]. Moreover, the urinary pH can influence the reabsorption of weak acids or bases. …

Epigenetic Dysregulation in Neurodegeneration: The Role of Histone Deacetylases and Emerging Inhibitor Strategies.

Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) are characterized by complex pathologies with progressive neurodegeneration, protein misfolding, oxidative stress, and persistent inflammation. Recent findings indicate the pivotal involvement of epigenetic disruption, particularly aberrant histone deacetylase (HDAC) activity, in disease initiation and progression. In the current review, we systematically discuss the mechanistic function of HDACs across all classes (I, IIa, IIb, III, and IV) in neurodegenerative disease mechanis

Совпадение в полном тексте источника
… Compound 4 , a benzylpiperazine-derived hydroxamic acid, was developed by Hashimoto et al. (2022) using a hybrid strategy that integrates HDAC6 inhibitory scaffolds with blood–brain barrier (BBB)-permeable features from H1-antihistamines like cetirizine for treating central nervous system (CNS) disorders …

Drug Repurposing for Cancer Treatment: A Comprehensive Review.

Cancer ranks among the primary contributors to global mortality. In 2022, the global incidence of new cancer cases reached about 20 million, while the number of cancer-related fatalities reached 9.7 million. In Saudi Arabia, there were 13,399 deaths caused by cancer and 28,113 newly diagnosed cases of cancer. Drug repurposing is a drug discovery strategy that has gained special attention and implementation to enhance the process of drug development due to its time- and money-saving effect. It involves repositioning existing medications to new clinical applications. Cancer treatment is a therap

Совпадение в полном тексте источника
… Metformin-decavanadate, vanadium-bisphosphonates, vanadyl(IV) complexes with non-steroidal anti-inflammatory drugs, and cetirizine and imidazole-based oxidovanadium(IV) complexes are examples [ 147 , 148 ]. 2.1.11. …

Evidence for the use of intravenous immunoglobulins--a review of the literature.

Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel

Hematology and Immune-Related Disorders

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 25th Европейский конгресс педиатрической ремуматологии (ПСР) 2018) Лиссабон, Португалия. 5-8 сентябрь 2018

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

2021 ACMT Annual Scientific Meeting Abstracts-Virtual.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

C

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

2020 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме книги для 27th Конгресс Европейской ассоциации гематологии

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.